Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06716151
PHASE1

A Study to Evaluate HB0034 in Healthy Chinese Adult Participants

Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

The aim of this study is to investigate the safety and tolerability of HB0034 in healthy subjects following a single dose or multiple dose.

Official title: A Phase I, Randomized, Double-blind, Placebo-controlled, Single/mulit Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HB0034 in Adult Healthy Subjects

Key Details

Gender

All

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2024-12-06

Completion Date

2025-11-20

Last Updated

2025-01-20

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

HB0034

Recombinant Humanized Anti-IL-36R Monoclonal antibody

DRUG

HB0034 matching placebo

HB0034 matching Palcebo

Locations (1)

Central Hospital affiliated to Shandong First Medical University

Jinan, Shandong, China